Back to Search
Start Over
Lenvatinib: Hyperbilirubinaemia and death: 2 case reports.
Lenvatinib: Hyperbilirubinaemia and death: 2 case reports.
- Source :
-
Reactions Weekly . 5/9/2020, Vol. 1803 Issue 1, p152-152. 1p. - Publication Year :
- 2020
-
Abstract
- B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a retrospective multicenter study involving 41 patients conducted between April 2018 and October 2018 in Japan, 2 patients were described who developed hyperbilirubinaemia (one patient) and died (one patient) during treatment with lenvatinib for advanced non-resectable hepatocellular carcinoma. However, one patient developed hyperbilirubinaemia requiring treatment discontinuation within 2 weeks of therapy initiation [ I outcome not stated i ]. The other patient died within 8 weeks of therapy initiation [ I immediate cause of death not stated i ]. [Extracted from the article]
Details
- Language :
- English
- ISSN :
- 01149954
- Volume :
- 1803
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Reactions Weekly
- Publication Type :
- Periodical
- Accession number :
- 143153620
- Full Text :
- https://doi.org/10.1007/s40278-020-78346-4